AlphaCrest Capital Management LLC boosted its holdings in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) by 160.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,454 shares of the company’s stock after acquiring an additional 34,176 shares during the period. AlphaCrest Capital Management LLC’s holdings in Allogene Therapeutics were worth $599,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Tudor Investment Corp Et Al acquired a new position in shares of Allogene Therapeutics during the 3rd quarter worth approximately $184,000. Point72 Asset Management L.P. acquired a new position in Allogene Therapeutics during the third quarter worth $3,167,000. Cubist Systematic Strategies LLC grew its holdings in Allogene Therapeutics by 110.8% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 579,245 shares of the company’s stock valued at $6,256,000 after buying an additional 304,445 shares in the last quarter. Moore Capital Management LP purchased a new stake in Allogene Therapeutics in the 3rd quarter valued at $1,296,000. Finally, Penserra Capital Management LLC increased its stake in shares of Allogene Therapeutics by 211.8% in the 3rd quarter. Penserra Capital Management LLC now owns 17,272 shares of the company’s stock worth $186,000 after acquiring an additional 11,732 shares during the last quarter. Institutional investors and hedge funds own 72.94% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. JMP Securities lowered their price target on shares of Allogene Therapeutics from $23.00 to $19.00 and set a “market perform” rating on the stock in a research report on Thursday, March 2nd. Robert W. Baird upgraded shares of Allogene Therapeutics from a “neutral” rating to an “outperform” rating and set a $12.00 target price on the stock in a report on Friday, January 6th. They noted that the move was a valuation call. Oppenheimer cut their price target on shares of Allogene Therapeutics from $32.00 to $28.00 and set an “outperform” rating for the company in a report on Wednesday, March 1st. B. Riley decreased their price objective on Allogene Therapeutics from $18.00 to $15.00 in a report on Wednesday, March 1st. Finally, HC Wainwright lowered their price objective on Allogene Therapeutics from $43.00 to $29.00 and set a “buy” rating for the company in a research report on Monday, November 21st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Allogene Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $18.67.
Allogene Therapeutics Stock Up 1.7 %
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last issued its quarterly earnings data on Tuesday, February 28th. The company reported ($0.66) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.05. Allogene Therapeutics had a negative return on equity of 43.44% and a negative net margin of 136,885.59%. The business had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.06 million. During the same period in the previous year, the firm posted ($0.54) earnings per share. The company’s revenue was down 6.0% on a year-over-year basis. Analysts anticipate that Allogene Therapeutics, Inc. will post -2.56 EPS for the current fiscal year.
Insider Buying and Selling at Allogene Therapeutics
In other news, General Counsel Veer Bhavnagri sold 5,602 shares of the stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $7.53, for a total transaction of $42,183.06. Following the sale, the general counsel now owns 583,677 shares of the company’s stock, valued at $4,395,087.81. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 11,602 shares of company stock valued at $83,853 in the last three months. 29.80% of the stock is owned by corporate insiders.
Allogene Therapeutics Profile
Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.
Read More
- Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
